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Background: Few reports have specifically addressed the efficacy of drug-eluting stents for chronic kidney disease patients.We sought to evaluate 
the effect of varying degrees of renal impairment on angiographic and clinical outcomes after treatment with sirolimus-eluting stents (SES) or 
paclitaxel-eluting stents (PES).
Methods: In the drug-eluting stent era, our institution used only SES from May 2004 to April 2007 and only PES from May 2007 to February 2009.
All consecutive patients treated with SES (SES-group; n=466) or PES (PES-group; 274) between May 2004 and February 2009 were analysed. 
According to estimated glomerular filtration rate (eGFR), all patients were stratified into 4 stages (stage I; 60 ≤ eGFR, stage II; 30 ≤ eGFR < 60, stage 
III; eGFR < 30 ml/min/1.73m2, stage IV; hemodialysis). The angiographic restenosis measured by quantitive coronary angiography at 8 months, and 
target-lesion revascularization (TLR) and major adverse cardiac events (MACE; death, myocardial infarction, and stroke) at 1 year were compared 
between groups.
Results: The angiographic restenosis rate was significantly lower in SES-group than PES-group with stage II (5.88% versus 21.2%; p<0.001), and 
stage III (7.27% versus 20.9%, p<0.05). Similarly, TLR was significantly lower in SES-group with stage II (1.10% versus 9.22%; p<0.001) and stage III 
(3.64% versus 16.3%; p<0.05). In the SES group, the in-stent restenosis rate and the incidence of TLR were not significantly different (p=0.92, 0.65) 
between patients at each stage (excluding stage IV). In the PES group, however, in-stent restenosis rate were significantly different (p<0.01) between 
patients at each stage of CKD.There were no significant differences of MACE, regardless of renal function (log-rank = NS).
Conclusions: These data suggest that use of an SES did not influence the in-stent restenosis rate and incidence of TLR, while use of a PES had a 
negative impact along with the progression of renal impairment, although it did not influence the incidence of MACE.
